Sudarshan Rajagopal

Dr. Sudarshan Rajagopal

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
SRSudarshan Rajagopal
Sudarshan Rajagopal
KRKeshava Rajagopal
Keshava Rajagopal
RLRobert J. Lefkowitz
Robert J. Lefkowitz

5 January 2018 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
JSJeffrey S Smith
Jeffrey S Smith
RLRobert J. Lefkowitz
Robert J. Lefkowitz
SRSudarshan Rajagopal
Sudarshan Rajagopal

9 August 2011 in Science Signaling
Verified
Journal Article
Closed access
PDF file
KNKelly N. Nobles
Kelly N. Nobles
KXKunhong Xiao
Kunhong Xiao
SASeungkirl Ahn
Seungkirl Ahn
ASArun K. Shukla
Arun K. Shukla
CLChristopher M. Lam
Christopher M. Lam
RLRobert J. Lefkowitz
Robert J. Lefkowitz
Phosphorylation of G protein–coupled receptors (GPCRs, which are also known as seven-transmembrane spanning receptors) by GPCR kinases (GRKs) plays essential roles in the regulation of receptor function by promoting interactions of the receptors with β-arrestins. These multifunctional adaptor proteins desensitize GPCRs, by reducing receptor coupling to G proteins and facilitating receptor internalization, and mediate GPCR signaling through β-arrestin–specific pathways. Detailed mapping of the phosphorylation sites on GPCRs targeted by individual GRKs and an understanding of how these sites regulate the specific functional consequences of β-arrestin engagement may aid in the discovery of therapeutic agents targeting individual β-arrestin functions. The β2-adrenergic receptor (β2AR) has many serine and threonine residues in the carboxyl-terminal tail and the intracellular loops, which are potential sites of phosphorylation. We monitored the phosphorylation of the β2AR at specific sites upon stimulation with an agonist that promotes signaling by both G protein–mediated and β-arrestin–mediated pathways or with a biased ligand that promotes signaling only through β-arrestin–mediated events in the presence of the full complement of GRKs or when either GRK2 or GRK6 was depleted. We correlated the specific and distinct patterns of receptor phosphorylation by individual GRKs with the functions of β-arrestins and propose that the distinct phosphorylation patterns established by different GRKs establish a “barcode” that imparts distinct conformations to the recruited β-arrestin, thus regulating its functional activities.

17 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SRSudarshan Rajagopal
Sudarshan Rajagopal
JKJihee Kim
Jihee Kim
SASeungkirl Ahn
Seungkirl Ahn
SCStewart Craig
Stewart Craig
CLChristopher M. Lam
Christopher M. Lam
RLRobert J. Lefkowitz
Robert J. Lefkowitz
Ubiquitously expressed seven-transmembrane receptors (7TMRs) classically signal through heterotrimeric G proteins and are commonly referred to as G protein-coupled receptors. It is now recognized that 7TMRs also signal through β-arrestins, which act as versatile adapters controlling receptor signaling, desensitization, and trafficking. Most endogenous receptors appear to signal in a balanced fashion using both β-arrestin and G protein-mediated pathways. Some 7TMRs are thought to be nonsignaling “decoys” because of their inability to activate typical G protein signaling pathways; it has been proposed that these receptors act to scavenge ligands or function as coreceptors. Here we demonstrate that ligand binding to the decoy receptor CXCR7 does not result in activation of signaling pathways typical of G proteins but does activate MAP kinases through β-arrestins in transiently transfected cells. Furthermore, we observe that vascular smooth muscle cells that endogenously express CXCR7 migrate to its ligand interferon-inducible T-cell alpha chemoattractant (ITAC), an effect that is significantly attenuated by treatment with either a CXCR7 antagonist or β-arrestin depletion by siRNA. This example of an endogenous “β-arrestin-biased” 7TMR that signals through β-arrestin in the absence of G protein activation demonstrates that some 7TMRs encoded in the genome have evolved to signal through β-arrestin exclusively and suggests that other receptors that are currently thought to be orphans or decoys may also signal through such nonclassical pathways.

1 March 2011 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
EWErin J. Whalen
Erin J. Whalen
SRSudarshan Rajagopal
Sudarshan Rajagopal
RLRobert J. Lefkowitz
Robert J. Lefkowitz

21 August 2011 in Nature
Verified
Journal Article
Open access
PDF file
MHMakoto R. Hara
Makoto R. Hara
JKJeffrey J. Kovacs
Jeffrey J. Kovacs
EWErin J. Whalen
Erin J. Whalen
SRSudarshan Rajagopal
Sudarshan Rajagopal
RSRyan T. Strachan
Ryan T. Strachan
RLRobert J. Lefkowitz
Robert J. Lefkowitz
Chronic stress is thought to lead to DNA damage, but the mechanisms involved are unclear. Here a molecular pathway is elucidated whereby stress-hormone activation of β2-adrenoreceptors triggers DNA damage and suppression of p53 levels through Gs-PKA and β-arrestin-1 signalling pathways. Cytosolic β-arrestin-1 facilitates activation of the E3 ligase Mdm2 by AKT, while nuclear β-arrestin-1 promotes Mdm2-mediated ubiquitination and degradation of p53. These results highlight the emerging role of β-arrestin-1 as an E3-ligase adaptor in the nucleus and reveal how DNA damage may accumulate in response to chronic stress. The human mind and body respond to stress1, a state of perceived threat to homeostasis, by activating the sympathetic nervous system and secreting the catecholamines adrenaline and noradrenaline in the ‘fight-or-flight’ response. The stress response is generally transient because its accompanying effects (for example, immunosuppression, growth inhibition and enhanced catabolism) can be harmful in the long term2. When chronic, the stress response can be associated with disease symptoms such as peptic ulcers or cardiovascular disorders3, and epidemiological studies strongly indicate that chronic stress leads to DNA damage4,5. This stress-induced DNA damage may promote ageing6, tumorigenesis4,7, neuropsychiatric conditions8,9 and miscarriages10. However, the mechanisms by which these DNA-damage events occur in response to stress are unknown. The stress hormone adrenaline stimulates β2-adrenoreceptors that are expressed throughout the body, including in germline cells and zygotic embryos11. Activated β2-adrenoreceptors promote Gs-protein-dependent activation of protein kinase A (PKA), followed by the recruitment of β-arrestins, which desensitize G-protein signalling and function as signal transducers in their own right12. Here we elucidate a molecular mechanism by which β-adrenergic catecholamines, acting through both Gs–PKA and β-arrestin-mediated signalling pathways, trigger DNA damage and suppress p53 levels respectively, thus synergistically leading to the accumulation of DNA damage. In mice and in human cell lines, β-arrestin-1 (ARRB1), activated via β2-adrenoreceptors, facilitates AKT-mediated activation of MDM2 and also promotes MDM2 binding to, and degradation of, p53, by acting as a molecular scaffold. Catecholamine-induced DNA damage is abrogated in Arrb1-knockout (Arrb1−/−) mice, which show preserved p53 levels in both the thymus, an organ that responds prominently to acute or chronic stress1, and in the testes, in which paternal stress may affect the offspring’s genome. Our results highlight the emerging role of ARRB1 as an E3-ligase adaptor in the nucleus, and reveal how DNA damage may accumulate in response to chronic stress.